- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04461600
A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer (TENACITY)
A Phase 2, Multi-center, Open-label, Single Arm Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Brussels, Belgium
- Institut Jules Bordet
-
Leuven, Belgium, 3000
- UZ Leuven
-
-
-
-
-
Haifa, Israel, 31096
- Rambam Medical Center
-
Jerusalem, Israel, 91120
- Hadassah Medical Center
-
Jerusalem, Israel, 9103102
- Shaare Zedek Hospital
-
Petah Tikva, Israel, 49100
- Rabin Medical Center
-
Reẖovot, Israel, 7661041
- Kaplan Medical Center
-
-
-
-
-
Barcelona, Spain, 8035
- Vall d'Hebron University Hospital
-
Barcelona, Spain, 8908
- Institut Catala d'Oncologia
-
Málaga, Spain, 29010
- Hospital Clinico Universitario Virgen de la Victoria
-
-
-
-
England
-
Manchester, England, United Kingdom, M204BX
- The Christie Hospital
-
-
Scotland
-
Edinburgh, Scotland, United Kingdom, EH42XR
- University Hospital of Edinburgh
-
-
-
-
Arizona
-
Gilbert, Arizona, United States, 85234
- Banner MD Anderson Cancer Center
-
Phoenix, Arizona, United States, 85054
- Mayo Clinic
-
-
California
-
San Francisco, California, United States, 94158
- University of California at San Francisco
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- University of Colorado
-
-
Florida
-
Jacksonville, Florida, United States, 32224
- Mayo Clinic
-
Saint Petersburg, Florida, United States, 33709
- Comprehensive Hematology Oncology
-
Tampa, Florida, United States, 33612
- H. Lee Moffitt Cancer Center
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- The University of Chicago
-
Urbana, Illinois, United States, 61801
- Carle Clinic
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- University of Louisville- James Brown Cancer Center
-
-
Maryland
-
Columbia, Maryland, United States, 20144
- Maryland Oncology Hematology
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
Missouri
-
Bolivar, Missouri, United States, 63613
- Central Cancer Care
-
-
New York
-
New York, New York, United States, 10065
- Memorial Sloan Kettering Cancer Center (MSKCC)
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- University Health Cleveland Medical Center
-
-
South Carolina
-
Charleston, South Carolina, United States, 29414
- Charleston Oncology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male of female subjects who are at least 18 years of age (inclusive) at the time of signing the Informed Consent Form (ICF).
- Have at least one measurable lesion per RECIST v1.1.
- Have formalin-fixed paraffin-embedded (FFPE) tissue available from a metastatic lesion; a tumor block or 25 unstained slides from an archived (within 2 years) or fresh tumor samples (core or punch needle biopsy) are acceptable.
- Documented tumor progression following no more than 3 lines of systemic chemotherapy, PARP inhibitor therapy or immunotherapy for metastatic disease, as appropriate. Of note, neoadjuvant and adjuvant therapy will not count as prior lines of therapy.
- Histologically confirmed diagnosis of inoperable locally advanced or metastatic TNBC defined as ER and progesterone receptor staining <10%, and HER2 negative defined as IHC 0 to 1+
- Documented Notch activation from tumor biopsy results from within the last 2 years from a commercially available NGS assay, LDT or other validated IUO clinical trial assay.
- Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test.
Exclusion Criteria:
- A known additional malignancy that is progressing or requires active treatment that is considered medically active and may interfere in the ability to detect responses in this subject. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that have undergone potentially curative therapy or in situ cervical cancer.
- BC that, in the opinion of the investigator, is considered amenable to potentially curative treatment.
- Symptomatic central nervous system (CNS) metastases.
- Current or recent (within 2 months of IP administration) gastrointestinal (GI) disease or disorders that increase the risk of diarrhea, such as inflammatory bowel disease and Crohn's disease.
- Developed immune-mediated colitis with immunotherapy unless resolved to G1 or lower and without requirement of steroid treatment for at least 14 days prior to first dose of IP.
- Peripheral neuropathy Grade 2 for at least 14 days prior to first dose of IP.
- Evidence of uncontrolled, active infection, requiring systemic anti-bacterial, anti-viral or anti-fungal therapy ≤7 days prior to administration of IP such as known active infection with hepatitis B, hepatitis C, or human immunodeficiency virus (HIV).
- Unstable or severe uncontrolled medical condition (e.g., unstable cardiac or pulmonary function or uncontrolled diabetes) or any important medical illness or abnormal laboratory finding that would, in the investigator's judgment, increase the risk to the subject associated with his or her participation in the study.
- Eastern Cooperative Oncology Group (ECOG) performance status ≥2.
Abnormal organ and marrow function defined as:
- neutrophils <1000/mm3,
- platelet count <75,000/mm3,
- hemoglobin <8 g/dL,
- total bilirubin >1.5 upper limit of normal (ULN) (except known Gilbert's syndrome whereby the total bilirubin must be < 5 mg/dL),
- aspartate aminotransferase (AST) and alanine aminotransferase (ALT) >2.5 ULN OR >5 ULN for subjects with liver metastases,
- creatinine clearance (CrCl) <50 mL/min (calculation of CrCl will be based on acceptable institution standard),
- uncontrolled triglyceride ≥Grade 2 elevations per CTCAE v5.0 (>300 mg/dL or >3.42 mmol/L).
- Myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities.
- Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥480 msec.
- Completed palliative radiation therapy < 7 days prior to initiating IP.
- Prior treatment with gamma secretase inhibitors.
- Last chemotherapy, biologic, or investigational therapy agent at least 4 weeks or 5 half-lives (whichever is shorter) prior to initiating IP; at least 6 weeks if the last regimen included BCNU or mitomycin C. Prior treatment with investigational monoclonal antibody will be reviewed case-by-case by the Sponsor.
- Receiving chronic systemic steroid therapy (in dosing exceeding 10 mg/day of prednisone or equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of IP. The use of physiologic doses of corticosteroids may be approved after consultation with the Sponsor.
- Use of strong inhibitors of CYP3A4 within 1 week or 5 half-lives (whichever is longer) or strong inducers of CYP3A4 within 2 weeks or 5 half-lives (whichever is longer).
- Life expectancy is less than 3 months.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: AL101
The study included a lead-in cohort with 6 subjects at 6mg AL101 weekly.
13 additional patients were treated with 4mg AL101 weekly.
|
AL101 is an inhibitor of gamma secretase-mediated Notch signaling.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Response Rate (ORR)
Time Frame: 12 month
|
ORR is defined as partial response (PR) + complete response (CR) as assessed by the investigator based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 for target lesions assessed by MRI. Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. |
12 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical Benefit Response Rate (CBR)
Time Frame: 12 month
|
Clinical benefit response rate (CBR) is defined as complete response (CR) + partial response (PR) + stable disease (SD) by investigator review based on RECIST v1.1 for target lesions assessed by MRI. Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Stable Disease (SD): Neither sufficient shrinkage (at least 30%) to qualify for PR nor sufficient increase (more than 20%) to qualify for PD, taking as reference the smallest sum diameters. |
12 month
|
Duration of Response (DOR) by Investigator Review Based on RECIST v1.1
Time Frame: 12 month
|
Duration of response (DOR) is defined as the time from randomization to disease progression or death in patients who achieve complete or partial response.
|
12 month
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Andres Gutierrez, MD, PhD, Executive Vice President & Chief Medical Officer
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AL-TNBC-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Triple Negative Breast Cancer
-
Peregrine PharmaceuticalsWithdrawnBreast Cancer | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | Triple-Negative Breast Cancer | Triple-Negative Breast Neoplasm | ER-Negative PR-Negative HER2-Negative Breast Neoplasms | ER-Negative PR-Negative HER2-Negative Breast Cancer
-
Swiss Group for Clinical Cancer ResearchNot yet recruitingTriple-negative Breast Cancer | TNBC - Triple-Negative Breast CancerSwitzerland
-
Washington University School of MedicineNational Cancer Institute (NCI); National Institutes of Health (NIH); MedImmune...TerminatedTriple Negative Breast Cancer | Triple Negative Breast Neoplasms | TNBC - Triple-Negative Breast Cancer | Triple-negative Breast CarcinomaUnited States
-
G1 Therapeutics, Inc.TerminatedBreast Cancer | Breast Neoplasm | Triple-Negative Breast Cancer | Triple-Negative Breast NeoplasmsUnited States, Bulgaria, Croatia, Slovenia, Serbia, Belgium, North Macedonia, Slovakia
-
AkesoRecruitingMetastatic Triple-negative Breast Cancer | Locally Advanced Triple-negative Breast CancerChina
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
Fudan UniversityNot yet recruitingTriple-negative Breast Cancer
-
Fudan UniversityRecruitingTriple-Negative Breast CancerChina
-
Fudan UniversityRecruiting
-
Fudan UniversityRecruiting
Clinical Trials on AL101
-
Ayala Pharmaceuticals, Inc,CompletedAdenoid Cystic CarcinomaUnited States, Canada, France, United Kingdom, Israel, Netherlands
-
M.D. Anderson Cancer CenterRecruitingAdenoid Cystic Carcinoma | Metastatic Adenoid Cystic CarcinomaUnited States
-
Alector Inc.Completed